Sanofi Pasteur: The vaccines division of Sanofi-Aventis Group

Image of adolescent child with basketball. Is your child protected?
Talk to your doctor

  1. Apicella MA. Neisseria meningitidis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pennsylvania: Churchill Livingstone; 2010:2737-2752.
  2. Tunkel AR, van de Beeks D, Scheld MW. Acute meningitis. In: Mandell GL, Bennett JE, Dolin R (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia; Pennsylvania: Churchill Livingstone Elsevier;2010:1189-1229.
  3. Menactra vaccine [Prescribing Information]. Swiftwater, Pennsylvania: Sanofi Pasteur Inc.; 2011.
  4. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book). 12th ed. Washington District of Columbia: Public Health Foundation; 2011.
  5. Sanofi Pasteur Inc. Data on file (Menactra vaccine: number of doses sold, 2005-2011), 2011. MKT23434.
  6. Scully EP, Baden LR, Katz JT. Fungal brain infections. Curr Opin Neurol. 2008;21(3):347-352.
  7. Logan SA, MacMahon E. Viral meningitis. BMJ. 2008;336(7634):36-40.
  8. Centers for Disease Control and Prevention. Notifiable diseases and mortality tables. MMWR. 2012;61(13):ND-170-ND-183.
  9. Munford RS, Suffredini AF. Sepsis, severe sepsis, and septic shock. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pennsylvania: Churchill Livingstone Elsevier; 2010:987-1010.
  10. Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502-e509.
  11. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737-739.
  12. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis. 1998;26(5):1159-1164.
  13. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196-2210.
  14. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159(10):907-913.
  15. Raza MM, Heyderman RS. Acute fever and headache - is it meningitis? J R Coll Physicians Edinb. 2006;36(3):232-235.
  16. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  17. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286(6):688-693.
  18. MacLennan J, Kafatos G, Neal K, et al; United Kingdom Meningococcal Carriage Group. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12(6):950-957.
  19. Thigpen MC, Whitney CG, Messonnier NE, et åal; Emerging Infections Programs Network. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364(21):2016-2025.
  20. CDC. Vaccines for Children Program (VFC): Information for parents from CDC. CS204495-C. May 2011.

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another, entirely independent website. Sanofi Pasteur provides this link as a service to its website visitors; however, it takes no responsibility for the information presented on any website but its own.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Close window and return to site.


Important Safety Information

Indication

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Safety Information

The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur.

Menactra vaccine is contraindicated in persons with a known hypersensitivity (eg, anaphylaxis) to any component of the vaccine. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks. Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions. Vaccination with Menactra vaccine may not protect all individuals.

Before administering Menactra vaccine, please see accompanying full Prescribing Information.